Literature DB >> 21958535

Defining the limits of radical cytoreductive surgery for ovarian cancer.

Jason D Wright1, Sharyn N Lewin, Israel Deutsch, William M Burke, Xuming Sun, Alfred I Neugut, Thomas J Herzog, Dawn L Hershman.   

Abstract

OBJECTIVE: Despite significant morbidity, surgical cytoreduction is the standard of care for ovarian cancer. We examined the outcomes of cytoreductive surgery to determine if there are groups of patients in which the morbidity is so substantial that alternate treatment strategies are warranted.
METHODS: The Nationwide Inpatient Sample was used to identify women who underwent surgery for ovarian cancer from 1998 to 2007. The effect of age, number of radical procedures performed, and clinical characteristics on morbidity and mortality were examined.
RESULTS: A total of 28,651 women were identified. The complication rates increased with age from 17.1% in those <50 years of age to 29.7% in women age 70-79 and to 31.5% in those ≥ 80 (p<0.05). The number of extended procedures performed was also a predictor of morbidity; complications increased from 20.4% for women with 0 procedures to 34.0% for 1 and 44.0% for ≥ 2 procedures (p<0.0001). In multivariable analysis age, comorbidity, and the number of procedures performed were the strongest predictors of outcome. The morbidity associated with additional procedures was greatest in the elderly. Medical complications in women <50 years of age occurred in 10.2% of those who underwent 0 radical procedures vs. 23.7% in those who underwent 2 or more procedures. For women ≥ 80 years, complications were noted in 18.3% for 0 procedures, and 33.3% for 2 or more procedures.
CONCLUSION: The morbidity of cytoreduction is greatest in elderly women where the effects of age and the number of radical procedures performed have an additive effect on complication rates.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21958535     DOI: 10.1016/j.ygyno.2011.08.027

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.482


  27 in total

1.  Safety and tolerance of radical hysterectomy for cervical cancer in the elderly.

Authors:  Erin M George; Ana I Tergas; Cande V Ananth; William M Burke; Sharyn N Lewin; Eri Prendergast; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2014-04-24       Impact factor: 5.482

2.  Predictive value of the Age-Adjusted Charlson Comorbidity Index on perioperative complications and survival in patients undergoing primary debulking surgery for advanced epithelial ovarian cancer.

Authors:  Rudy S Suidan; Mario M Leitao; Oliver Zivanovic; Ginger J Gardner; Kara C Long Roche; Yukio Sonoda; Douglas A Levine; Elizabeth L Jewell; Carol L Brown; Nadeem R Abu-Rustum; Mary E Charlson; Dennis S Chi
Journal:  Gynecol Oncol       Date:  2015-05-31       Impact factor: 5.482

3.  Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Authors:  Sonali Patankar; William M Burke; June Y Hou; Ana I Tergas; Yongmei Huang; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Gynecol Oncol       Date:  2015-05-11       Impact factor: 5.482

4.  Complications and Survivorship Trends After Primary Debulking Surgery for Ovarian Cancer.

Authors:  Zhaomin Xu; Adan Z Becerra; Carla F Justiniano; Christopher T Aquina; Fergal J Fleming; Francis P Boscoe; Maria J Schymura; Abdulrahman K Sinno; Jessica Chaoul; Gary R Morrow; Lori Minasian; Sarah M Temkin
Journal:  J Surg Res       Date:  2019-09-24       Impact factor: 2.192

5.  Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care.

Authors:  A K Sinno; X Li; R E Thompson; E J Tanner; K L Levinson; R L Stone; S M Temkin; A N Fader; D S Chi; K Long Roche
Journal:  Gynecol Oncol       Date:  2017-03-30       Impact factor: 5.482

6.  Development and validation of a risk-calculator for adverse perioperative outcomes for women with ovarian cancer.

Authors:  Stephanie Cham; Ling Chen; Caryn M St Clair; June Y Hou; Ana I Tergas; Alexander Melamed; Cande V Ananth; Alfred I Neugut; Dawn L Hershman; Jason D Wright
Journal:  Am J Obstet Gynecol       Date:  2019-02-13       Impact factor: 8.661

7.  Intraoperative Handoffs and Postoperative Complications Among Patients Undergoing Gynecologic Oncology Operations.

Authors:  Kemi M Doll; Jessica A Lavery; Anna C Snavely; Paola A Gehrig
Journal:  J Healthc Qual       Date:  2017 Jul/Aug       Impact factor: 1.095

8.  Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  Gynecol Oncol       Date:  2016-08-08       Impact factor: 5.482

9.  Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer: Society of Gynecologic Oncology and American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Alexi A Wright; Kari Bohlke; Deborah K Armstrong; Michael A Bookman; William A Cliby; Robert L Coleman; Don S Dizon; Joseph J Kash; Larissa A Meyer; Kathleen N Moore; Alexander B Olawaiye; Jessica Oldham; Ritu Salani; Dee Sparacio; William P Tew; Ignace Vergote; Mitchell I Edelson
Journal:  J Clin Oncol       Date:  2016-08-08       Impact factor: 44.544

10.  Measurement and validation of frailty as a predictor of outcomes in women undergoing major gynaecological surgery.

Authors:  E M George; W M Burke; J Y Hou; A I Tergas; L Chen; A I Neugut; C V Ananth; D L Hershman; J D Wright
Journal:  BJOG       Date:  2015-08-23       Impact factor: 6.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.